Jasper Therapeutics financials
$0.6254−0.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-3.95 | $-4.89 | $-6.18 | $-10.33 | $-26.90 |
| EBITDA | -$82.8M | -$74.9M | -$67.8M | -$50.2M | -$36.3M |
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Free cash flow | -$77.2M | -$63.2M | -$52.3M | -$46.4M | -$36.1M |
| Diluted shares | 19.2M | 14.6M | 10.4M | 3.6M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $28.7M | $71.6M | $86.9M | $38.3M | $84.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $18.0K | $0.00 |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.2M | $24.1M |
| Shareholders' equity | $4.2M | $61.7M | $78.4M | $36.1M | $69.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology